GlassScriptPhysician profile
Lauren Wislocki
NPI 1427866706
$526.56
in general payments reported to CMS, 2019-2025
14 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461 · Education: $65.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.12 |
| Education | $65.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $102.27 | 2025 | |
| Amgen INC. | $82.70 | 2025 | Evenity |
| Astrazeneca Pharmaceuticals LP | $65.44 | 2025 | Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $49.26 | 2025 | Keytruda, Lynparza |
| Karyopharm Therapeutics INC. | $28.52 | 2025 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $26.22 | 2025 | |
| Glaxosmithkline, LLC. | $25.94 | 2025 | Ojjaara |
| Sumitomo Pharma America, INC. | $24.61 | 2025 | Orgovyx |
| Takeda Pharmaceuticals U.S.A., INC. | $22.68 | 2025 | Iclusig |
| Gilead Sciences, INC. | $21.51 | 2025 | Trodelvy |
| Array Biopharma INC | $21.51 | 2025 | Mektovi, Braftovi, Lorbrena |
| Genzyme Corporation | $19.36 | 2025 | |
| Stemline Therapeutics INC. | $19.08 | 2025 | Orserdu |
| Azurity Pharmaceuticals, INC. | $17.46 | 2025 | Danziten, Vivimusta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Wislocki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.